Joana Carvalho, PhD, managing science editor —

The Hereditary Neuropathy Foundation (HNF) has launched a new virtual fitness platform to promote the practice of safe physical activity among patients with Charcot-Marie-Tooth (CMT) disease. The “Movement is Medicine” Fitness Ambassador program will enable members of HNF’s Movement is Medicine initiative to have access to weekly live…

This summer, the Charcot-Marie-Tooth Association (CMTA) turned its annual Camp Footprint for children and teens with CMT disease into a virtual experience. The unique initiative, which was launched by the CMTA in 2016, seeks to provide a safe sleepaway camp environment where children and adolescents with…

The chemotherapy agent oxaliplatin does not increase the risk of chemotherapy-induced peripheral neuropathy (CIPN), one of its most common side effects, in patients with uncommon variants in genes that cause Charcot-Marie-Tooth (CMT) disease, a study found. Treatment with oxaliplatin should not be interrupted if such genetic variants are…

Scientists have described a new genetic mutation in the PMP22 gene associated with a severe and early-onset form of Charcot-Marie-Tooth disease type 1A (CMT1A) in a 9-year-old girl. The case was reported in the study, “A novel homozygous variant extending the peripheral myelin protein…

Women with Charcot-Marie-Tooth (CMT) disease do not have a higher rate of pregnancy or delivery complications than women who do not have the disease, a study has found. The study, “Pregnancy outcome in Charcot‐Marie‐Tooth disease: results of the CMT‐NET cohort study in Germany,” was published in…

Pharnext’s oral experimental treatment PXT3003 was found to be safe and effective for patients with Charcot-Marie-Tooth type 1A (CMT1A), improving clinical outcomes and stabilizing disease progression over the course of two years of treatment, according to data from a Phase 3 trial and its open-label extension study.

Charcot-Marie-Tooth disease type 1A (CMT1A) caused by a duplication in the DNA sequence of the PMP22 gene was the most common form of this disease found in a large group of patients in southern Italy, a study reports. This finding supports suggestions that disease-causing mutations in…

A small RNA molecule called miR-29a can prevent Schwann cells from producing abnormal PMP22 transcripts associated with Charcot-Marie-Tooth disease type 1A (CMT1A), a study has found. The study, “Downregulation of the human peripheral myelin protein 22 gene by miR-29a in cellular models of Charcot–Marie–Tooth disease,”…

The Muscular Dystrophy Association (MDA) has awarded 25 research grants totaling more than $6.6 million to scientists working on different neuromuscular diseases (NMDs), including Charcot-Marie-Tooth disease (CMT). This round of grant funding builds on the more than $1 billion the MDA has already invested to promote the discovery…

The Charcot–Marie–Tooth Association (CMTA) has granted $335,000 to two research projects focused on the development of new therapies for Charcot–Marie–Tooth (CMT) disease type 1A, type 1B, and other demyelinating forms of CMT, including type 4. CMTA has been funding projects for 30 years on…